References
- Calvert AH (2004). Biochemical pharmacology of Pemetrexed. Oncol (Williston Park), 18, 13-7.
- Cripps C, Burnell M, Jolivet J, et al (1999). Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol, 10, 1175-9. https://doi.org/10.1023/A:1008372529239
- C. Louvet (2004). Pemetrexed in advanced colorectal cancer. Oncology (Williston Park), 18, 56-62.
- Cao J, Huang XE, Liu J, Wu XY, Lu YY (2013). Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev, 14, 7171-7. https://doi.org/10.7314/APJCP.2013.14.12.7171
- Chen YS, Xu SX, Ding YB, et al (2013). Helicobacter pylori Infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. Asian Pac J Cancer Prev, 14, 7613-9. https://doi.org/10.7314/APJCP.2013.14.12.7613
- Chen YS, Xu SX, Ding YB, et al (2013). Colorectal cancer screening in high-risk populations: a survey of cognition among medical professionals in Jiangsu, China. Asian Pac J Cancer Prev, 14, 6487-91. https://doi.org/10.7314/APJCP.2013.14.11.6487
- de Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47.
- Derwinger K, Kodeda K, Swartling T, et al (2011). A phase I/ II study of neoadjuvant chemotherapy with pemetrexed (Alimta) in rectal cancer. Eur J Surg Oncol, 37, 583-8 https://doi.org/10.1016/j.ejso.2011.04.003
- De Gramont A, Kindler HL (2002). Pemetrexed in patients with gastrointestinal carcinoma. Semin Oncol, 29, 42-49. https://doi.org/10.1053/sonc.2002.30763
- Douillard JY, Cunningham D, Roth AD, et al (2000).Irinotecan combined with fluorouracil compared with fluorouracil alone. As first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 25, 1041-7.
- Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M (2004). Synergistic cytotoxicity and pharmacogenetics of gemcitabine andpemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res, 10, 2936-43 https://doi.org/10.1158/1078-0432.CCR-03-0520
- Gong JP, Yang L, Huang XE, et al (2014). Outcomes based on risk assessment of anastomotic leakage after rectal cancer surgery. Asian Pac J Cancer Prev, 15, 707-12. https://doi.org/10.7314/APJCP.2014.15.2.707
- Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
- Huang XE, Tian GY, Cao J, et al (2013). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7. https://doi.org/10.7314/APJCP.2013.14.11.6663
- Hochster HS (2004). The role of pemetrexed in the treatment of gastrointestinal malignancy. Clin Colorectal Cancer, 4, 190-5. https://doi.org/10.3816/CCC.2004.n.019
- Hanauske AR, Chen V, Paoletti P, et al (2001). Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. The Oncologist, 6, 363-373. https://doi.org/10.1634/theoncologist.6-4-363
- Jackman DM (2009). Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg, 21, 154-8. https://doi.org/10.1053/j.semtcvs.2009.06.010
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90 https://doi.org/10.3322/caac.20107
- Kohne CH, Van Cutsem E, Wils J, et al (2005). Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol, 23, 4856-65. https://doi.org/10.1200/JCO.2005.05.546
- John W, Picus J, Blanke CD et al (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer, 88, 1807-13. https://doi.org/10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
- Jones RJ, Twelves CJ (2002). Pemetrexed:a multitargeted antifolate (ALIMTA, LY-231514)[J]. Expert Rev Anticancer Ther, 2, 13-22. https://doi.org/10.1586/14737140.2.1.13
- Louvet C, de Gramont A (2004). Pemetrexed in advanced colorectal cancer. Oncology (Williston Park), 18, 56-62.
- Lu YY, Huang XE, et al (2014), Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Asian Pac J Cancer Prev, 15, 3335-41. https://doi.org/10.7314/APJCP.2014.15.7.3335
- Mabro M, Louvet C, Andre T, et al (2003). Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol, 26, 254-8.
- Manegold C, Schmid-Bindert G, Pilz LR (2009). Pemetrexed for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther, 9, 1195-209. https://doi.org/10.1586/era.09.97
- Mabro M, Artru P, Andre T, et al (2006). A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer, 8, 1287-92.
- Goldberg RM, Sargent DJ, Morton RF, et al (2004). A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 1, 23-30.
- Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Saltz LB, Cox JV, Blanke C, et al (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 28, 905-14.
- Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin pluspemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51 https://doi.org/10.1200/JCO.2007.15.0375
- John W, Picus J, Blanke CD, et al (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer, 88, 1807-13. https://doi.org/10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
- Wei GL, Huang XE, Huo JG, Wang XN, Tang JH (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6. https://doi.org/10.7314/APJCP.2013.14.5.2703
- Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. https://doi.org/10.7314/APJCP.2013.14.3.2019
- Xiao Y, Liu J, Liu YC, Huang XE, et al (2014). Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy. Asian Pac J Cancer Prev, 15, 3951-4. https://doi.org/10.7314/APJCP.2014.15.9.3951
- Xu C, Huang XE, et al (2014). Drainage alone or combined with anti-tumor therapy for treatment of obstructive jaundice caused by recurrence and metastasis after primary tumor resection. Asian Pac J Cancer Prev, 15, 2681-4. https://doi.org/10.7314/APJCP.2014.15.6.2681
- Yang L, Huang XE, et al (2013). Role of MYH polymorphisms in sporadic colorectal cancer in China: a case-control, population-based study. Asian Pac J Cancer Prev, 14, 6403-9. https://doi.org/10.7314/APJCP.2013.14.11.6403
- Yang L, Huang XE, et al (2013). Acidic pelvic drainage as a predictive factor for anastomotic leakage after surgery for patients with rectal cancer. Asian Pac J Cancer Prev, 14, 5441-7. https://doi.org/10.7314/APJCP.2013.14.9.5441
Cited by
- Effects of Analgecine on Oxaliplatin-Induced Neurotoxicity in Patients with Gastrointestinal Cancer vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4465
- Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.647
- Effect of CXCR4 and CD133 Co-expression on the Prognosis of Patients with Stage II~III Colon Cancer vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1073
- Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3395
- Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3425
- Pemetrexed in Treating Patients with Metastatic Bladder Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3839
- Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
- A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485